Guidant News

The FDA has cleared a device made by Boston Scientific Corp. of Natick for an alternative to existing methods to remove large common bile duct stones.

Belo Sun Mining Corp. is pleased to announce that it has acquired the material surface rights at its 100% owned Volta Grande gold project in Para State, Brazil.

"To get lifesaving drugs and devices to the patients that need them as quickly as possible, Congress must give the Food and Drug Administration the tools it needs to review and approve these products," Senate Majority Leader Harry Reid stated on the Senate floor.

There's an old saying on Wall Street about insider buying: there are many possible reasons to sell a stock, but only one reason to buy.

Shares of Boston Scientific Corporation ended the trading session lower by $0.12 or -1.89% from its previous close.

Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing.

NATICK, Mass., May 18, 2012 /PRNewswire/ -- Boston Scientific Corporation announces two-year results from the PLATINUM Small Vessel study, demonstrating excellent safety and effectiveness outcomes for the 2.25 mm PROMUS Element Everolimus-Eluting Platinum Chromium Stent System in treating de novo coronary lesions in small coronary vessels.

Boston Scientific Corporation announces U.S. Food and Drug Administration approval and market launch of the Epica Vascular Self-Expanding Stent System.

Follow-up Data from EVOLVE Trial Presented at EuroPCR; Trial is Evaluating Next-Generation Everolimus-Eluting Platinum Chromium Coronary Stent with Ultra-Thin Bioabsorbable Abluminal Polymer /PRNewswire/ -- Boston Scientific Corporation announces that the SYNERGYTM Everolimus-Eluting Bioabsorbable Polymer-Coated Platinum Chromium Coronary Stent ... (more)

Boston Scientific Corporation announces results from the REPRISE I feasibility trial, which evaluated the acute safety of the Lotus Aortic Valve System in patients with severe aortic valve disease.

The firm currently has a "neutral" rating on the stock. The analysts wrote, "In March 2004, Boston Scientific entered an unprecedented new product cycle for a large-capital medical technology company with the U.S. launch of the TAXUS stent.

The data showed a reduction in the risk of ischemic stroke by 75 percent in patients with atrial fibrillation who have a contraindication to oral anticoagulants such as warfarin.

Boston Scientific's current acquisition, Cameron Health, reports that its implantable heart defibrillator was safe and effective in a trial involving 330 patients.

Developments, news and strategies for drug development specific to phase I through Phase III global clinical trial management, execution, project management and outsourcing.

Fresh off positive first-quarter earnings and Food and Drug Administration approval of key devices, the $7.8 billion company, which specializes in cardiovascular aids such as drug-coated stents and defibrillators, is touting its "rejuvenated, revitalized product pipeline" and a three-pronged strategy for global expansion as it holds its annual ... (more)

Boston Scientific Corporation scores FDA approval, and announces market intro of its Ingenio and Advantio pacemakers and Invive cardiac resynchronization therapy pacemakers.

Boston Scientific Corp. 's Ingenio and Advantio pacemakers won U.S. approval to treat abnormally slow heartbeats, clearing the way for sales of devices that have been in development for a decade in the $4 billion global market.

The pile of lawsuits is growing against Natick-based Boston Scientific and rival manufacturers over vaginal mesh inserts that were used to help with incontinence or a condition known as pelvic organ prolapse, the Patriot Ledger reports.

Deborah was formerly at Guidant Corporation as a Director of R&D and New Ventures, and she currently has various advisory roles for the Georgia Institute of Technology, the Dystonia Medical Research Foundation, and the Association of Women in Science.